"Sulfonylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013453
|
| MeSH Number(s) |
D02.886.590.795 D02.948.828
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Sulfonylurea Compounds".
This graph shows the total number of publications written about "Sulfonylurea Compounds" by people in this website by year, and whether "Sulfonylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 3 | 4 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonylurea Compounds" by people in Profiles.
-
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. BMJ Open Diabetes Res Care. 2026 May 21; 14(3).
-
Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. BMJ Open Diabetes Res Care. 2026 Feb 26; 14(1).
-
Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial. Endocr Pract. 2026 Jun; 32(6):916-926.
-
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocr Pract. 2026 Jan; 32(1):23-30.
-
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk. J Am Heart Assoc. 2025 Aug 05; 14(15):e040217.
-
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Res Care. 2025 Apr 23; 13(2).
-
GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngol Head Neck Surg. 2025 Mar 01; 151(3):243-252.
-
Food Insecurity and Hypoglycemia among Older Patients with Type 2 Diabetes Treated with Insulin or Sulfonylureas: The Diabetes & Aging Study. J Gen Intern Med. 2024 Oct; 39(13):2400-2406.
-
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmol Retina. 2024 Oct; 8(10):943-952.
-
A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life. Diabetologia. 2024 May; 67(5):940-951.